Evidence map›Paper›PMID 38197000›Full record

ArticleTranslational and clinical pharmacology2023

Pharmacokinetic properties of a new sustained-release pregabalin tablet in subjects with reduced renal function.

Maria Park, Suein Choi, Sungpil Han, Wonsuk Shin, Anhye Kim, Seunghoon Han, Bomin Kim, Yeji Lim, Hyounggyoon Yoo

Registry-linked trialOpen access · diamondAbstract read
In one paragraph

Article in Translational and clinical pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05012436 (A Study to Evaluate the Pharmacokinetics and Safety Following a Single Oral Dose of YHD1119 in Subjects With Renal Impairment and Healthy Subjects), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 70% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05012436 phase1completednot on this map

A Study to Evaluate the Pharmacokinetics and Safety Following a Single Oral Dose of YHD1119 in Subjects With Renal Impairment and Healthy Subjects

TypeinterventionalSponsorYuhan CorporationRan2021 to 2022Enrolled16ConditionsHealthy Volunteer, Renal ImpairmentsArmsYHD1119 75mg
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Maria ParkDepartment of Clinical Pharmacology and Therapeutics, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul 06591, Korea.ORCID https://orcid.org/0009-0006-6817-2767
Suein ChoiDepartment of Clinical Pharmacology and Therapeutics, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul 06591, Korea.ORCID https://orcid.org/0000-0001-5438-7819
Sungpil HanDepartment of Clinical Pharmacology and Therapeutics, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul 06591, Korea.ORCID https://orcid.org/0000-0002-4674-7682
Wonsuk ShinDepartment of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, Seongnam 13520, Korea.ORCID https://orcid.org/0000-0002-6163-5726
Anhye KimDepartment of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, Seongnam 13520, Korea.ORCID https://orcid.org/0000-0002-6622-8089
Seunghoon HanDepartment of Clinical Pharmacology and Therapeutics, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul 06591, Korea.ORCID https://orcid.org/0000-0002-9976-5120
Bomin KimClinical Development and Medical Division, Yuhan Corporation, Seoul 06927, Korea.ORCID https://orcid.org/0009-0008-1537-8918
Yeji LimClinical Development and Medical Division, Yuhan Corporation, Seoul 06927, Korea.ORCID https://orcid.org/0000-0001-7143-4656
Hyounggyoon YooDepartment of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, Seongnam 13520, Korea.ORCID https://orcid.org/0000-0003-2785-4383
The Catholic University of Korea Seoul St. Mary's Hospital · KRCHA University Bundang Medical Center · KRYuhan (South Korea) · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new sustained-release (SR) pregabalin tablet, YHD1119, was formulated for once-daily dosing. In the current study, we aimed to evaluate the pharmacokinetics of YHD1119 tablets in patients with reduced renal function. Subjects were grouped by creatinine clearance: > 60 mL/min/1.73m Trial Registration: ClinicalTrials.gov Identifier: NCT05012436.

Indexed as

Delayed-Action PreparationsPharmacokineticsPregabalinRenal Insufficiency

Identifiers

PMID38197000
PMCPMC10772055
OpenAlexW4390297960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.